Cargando…

Therapeutic stromal nanoparticles for Parkinson’s disease

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Company of Biologists Limited 2014
Materias:	In This Issue
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174531/

Ejemplares similares

New mouse model for Parkinson’s disease
Publicado: (2013)

Neuroprotection by Nrf2 in Parkinson’s disease model
Publicado: (2011)

Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics
por: Bandres‐Ciga, Sara
Publicado: (2022)

The Parkinson's Disease DNA Variant Browser
por: Kim, Jonggeol J., et al.
Publicado: (2021)

Diabetes and Neuroaxonal Damage in Parkinson's Disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)

The Myelin‐Weighted Connectome in Parkinson's Disease
por: Boshkovski, Tommy, et al.
Publicado: (2021)

Neuromelanins in brain aging and Parkinson's disease: synthesis, structure, neuroinflammatory, and neurodegenerative role
por: Zucca, Fabio A., et al.
Publicado: (2022)

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease
por: Quattrone, Andrea, et al.
Publicado: (2022)

The prodromes of Parkinson's disease
por: Rees, Richard Nathaniel, et al.
Publicado: (2018)

TorsinA: a therapeutic target for ALS?
Publicado: (2014)

Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
por: Vila, Miquel
Publicado: (2019)

The Impact of Type 2 Diabetes in Parkinson's Disease
por: Athauda, Dilan, et al.
Publicado: (2022)

Hypothermia: a cool therapeutic approach for AD-HSP?
Publicado: (2014)

Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
por: Dommershuijsen, Lisanne J., et al.
Publicado: (2020)

Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review
por: Carey, Guillaume, et al.
Publicado: (2020)

Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource
por: Iwaki, Hirotaka, et al.
Publicado: (2021)

A Multi‐Step Model of Parkinson's Disease Pathogenesis
por: Le Heron, Campbell, et al.
Publicado: (2021)

Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
por: Omer, Nurit, et al.
Publicado: (2021)

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease
por: Pagan, Fernando L., et al.
Publicado: (2020)

Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease
por: Heilman, Patrick L., et al.
Publicado: (2020)

The Parkinson's Disease Genome‐Wide Association Study Locus Browser
por: Grenn, Francis P., et al.
Publicado: (2020)

Cerebello‐Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease
por: Helmich, Rick C., et al.
Publicado: (2021)

Cerebrospinal Fluid Cytokines and Neurodegeneration‐Associated Proteins in Parkinson's Disease
por: Wijeyekoon, Ruwani S., et al.
Publicado: (2020)

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
por: Werner, Milton H., et al.
Publicado: (2021)

MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease
por: Metcalfe‐Roach, Avril, et al.
Publicado: (2021)

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021)

Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
por: Campese, Nicole, et al.
Publicado: (2021)

Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease
por: Onofrj, Marco, et al.
Publicado: (2021)

Self‐Report versus Clinician Examination in Early Parkinson's Disease
por: Zolfaghari, Sheida, et al.
Publicado: (2021)

Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk
por: Lake, Julie, et al.
Publicado: (2021)

Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease
por: Wang, Shijie, et al.
Publicado: (2022)

Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease
por: Murtomäki, Kirsi, et al.
Publicado: (2022)

Gait‐Related Metabolic Covariance Networks at Rest in Parkinson's Disease
por: Sigurdsson, Hilmar P., et al.
Publicado: (2022)

Glycosphingolipid Changes in Plasma in Parkinson's Disease Independent of Glucosylceramide Levels
por: te Vruchte, Danielle, et al.
Publicado: (2022)

Preclinical Evaluation of the Safety and Efficacy of Cryopreserved Bone Marrow Mesenchymal Stromal Cells for Corneal Repair
por: Putra, Ilham, et al.
Publicado: (2021)

TWNK in Parkinson's Disease: A Movement Disorder and Mitochondrial Disease Center Perspective Study
por: Percetti, Marco, et al.
Publicado: (2022)

Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease
por: Kane, Patrick Bodilly, et al.
Publicado: (2020)

Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms
por: van der Heide, Anouk, et al.
Publicado: (2020)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease
por: Wilson, Joanna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q64r68t575au9d1bfk4itt9bae